ASX Announcement November 15, 2021

CLTX CAR T PRESENTS POSITIVE INITIAL PHASE 1 CLINICAL DATA

- **75% disease control rate seen at lowest dose level of CLTX CAR T cells**
- **CLTX CAR T was generally well tolerated with no dose limiting toxicities**
- **Persistence of CLTX CAR T cells shown throughout treatment**
- **Results give Chimeric confidence as higher dose levels and dual routes of administration commence**
- **Webinar to be held at 9:30am AEDT today discussing the results. Click here to register.**

Chimeric Therapeutics (ASX:CHM, "Chimeric"), a clinical-stage cell therapy company and the ASX leader in cell therapy, is pleased to highlight the release of two CLTX CAR T abstracts for presentation at the Society for Neuro-Oncology (SNO) 27th annual scientific meeting which have shown positive results from Chimeric's CLTX CAR T phase 1 clinical trial.

Abstract CTIM-29, "*Clinical evaluation of chlorotoxin-directed CAR T cells for patients with recurrent glioblastoma"* provides insight into the initial clinical data for CLTX while abstract EXTH-10, "*Exploration of a novel toxin-incorporating CAR T cell: how does chlorotoxin recognize glioblastoma cells*?" expands on the translational understanding of Chlorotoxin (CLTX) activity.

The clinical data released in abstract CTIM-29 is from the ongoing CLTX CAR T phase 1 clinical trial in patients with MMP2+ recurrent or progressive glioblastoma. The data focuses on the four patients enrolled in dose level 1 of the trial, treated with 44 X 10^6 CLTX CAR T cells through a single route of intratumoral administration. Dose escalation in this trial is planned across four dose levels to a total dose of 440 X 10^6 CLTX CAR T cells administered through dual intratumoral and intraventricular routes of administration.

Within patients treated at dose level 1, a disease control rate of 75% was shown as three out of the four patients treated achieved a best response of stable disease assessed by RANO (response assessment in neuro-oncology).

The CLTX CAR T cells were generally well tolerated and none of the patients experienced a dose limiting toxicity. One patient experienced a grade 3 cerebral edema that was only possibly attributed to the CAR T cells. Cerebral edema is an adverse event commonly observed in patients with glioblastoma.

Bioactivity of the cells was also demonstrated as liquid biopsy detected persistent CLTX CAR T cells in the tumour cavity throughout treatment, suggesting that the CLTX CAR T cells are not immunogenic (an immune response that can impact the persistence and efficacy of the CAR T).

Chimeric's CEO and Managing Director Jennifer Chow said: *"These initial CLTX CAR T clinical data, while early, are highly encouraging as they demonstrate that CLTX CAR T cells are eliciting disease control in recurrent glioblastoma even at the lowest, sub-therapeutic dose level. Achieving disease control in 3 of the 4 patients treated at this first dose level, along with the generally well tolerated safety profile that was demonstrated, provides us with great enthusiasm for progressing the trial through the higher dose levels and dual routes of administration."*

The translational data available in abstract EXTH-10 focuses on the precise composition and structure of the cell surface complex recognized by CLTX CAR T, confirming that the correlation between MMP-2 expression and CLTX binding supports the rationale for exploring MMP-2 as a correlative marker for response to CLTX CAR T in Phase 1 studies.

Additional insight may be provided on November 19 when the abstracts are fully presented at the SNO meeting.

About the CLTX CAR T (CHM 1101) Clinical Trial:

The CLTX CAR T phase 1 clinical trial is currently in progress at a single site in California with plans to expand to a multi-site trial in 2022. The design is a single arm, open label trial in patients with MMP2+ recurrent or progressive glioblastoma.

The primary endpoints of the trial are to assess the safety of CLTX CAR T cells, determine the maximum tolerated dose schedule and a recommended Phase 2 dosing plan. Secondary endpoints include bioactivity and efficacy measures.

The trial is designed with 4 dose levels ranging from 44 X 10^6 to 440 X 10^6 CLTX CAR T cells and studies both single and dual routes of administration of cells. Dose level 1 was completed with no dose limiting toxicities in April 2021.



Investor webinar

Chimeric Therapeutics CEO and Managing Director Jennifer Chow, alongside Executive Chairman Paul Hopper, will hold an investor webinar today, Monday 15 November 2021, at 9:30am AEDT to discuss the initial Phase 1 data.

Click the link below to register:
https://us02web.zoom.us/webinar/register/WN_sd6SHoOcQI2OLMJYJhmqZw

After registering, you will receive a confirmation email about how to join the webinar. A recording of the webinar will be available at the same link shortly after the conclusion of the session.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and the ASX leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy for the treatment of patients with Glioblastoma (GBM). CHM 1101 was developed by scientists at the City of Hope Medical Centre in California where it is currently being studied in a phase 1 clinical trial.

Chimeric also recently announced the expansion of their pipeline with the exclusive licensing of CHM 2101, a novel, 3rd generation CDH17 CAR T invented at the University of Pennsylvania. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in 2022 in Neuroendocrine Tumours, Colorectal, Pancreatic and Gastric Cancer.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

CONTACT

Investors
Jennifer Chow
Chief Executive Officer and Managing Director
Chimeric Therapeutics
T: + 1 9087238387
E: jchow@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Paul Hopper
Executive Chairman
T: + 61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media
Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au